All Lundquist Institute articles
-
NewsPioneering oral fungal infection treatment shows promise in preclinical trials
A novel oral amphotericin B (MAT2203) developed for treatment of invasive mucormycosis (IM) and other deadly invasive fungal infections, has demonstrated encouraging results in a series of preclinical studies.
-
NewsMonoclonal antibody programme targets mucormycosis
Vitalex Biosciences has been awarded an SBIR Phase 2 grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health for VX-01, a monoclonal antibody (mAB) programme targeting the debilitating indication of the fungal disease, mucormycosis.
